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Studies havedemonstrated that lipid rafts ultimately regulate the endocytosis of anthrax toxin via clathrin
dependent pathway. Interestingly, GPI-anchoredprotein rich rafts have also been shown tobe transported
down to the endocytic pathway to reducing late endosomes. Taking advantage of this parallelism, we
tried translating the anthrax toxin natural intoxication mechanism by administering a DNA chimera
that encoded protective antigen attached to a mammalian GPI-anchor sequence at its C-terminus (pGPI-
PA63). We also designed a chimera that had an additional N-terminal TPA leader sequence (pTPA.GPI-
PA63) with an aim to target GPI-PA63 to ER where new CD1 molecules are synthesized. Analysis of
antibody titers demonstrated successful priming and potential IgG titers after the first boost. In vitro
cell proliferation studies in the presence of GPI-attached PA63 peptides revealed that there was a clonal
expansion of CD4+ NK1.1+ helper T cell population which rapidly produced IL-4 in response to T cell
receptor ligation. These cells provided direct B cell help that aided IgG formation. Effector responses
generated by NKT cells were found to be MHC II-independent and CD1d-restricted. In addition, the group
pTPA.GPI-PA63 also displayed low magnitude MHC-II restricted (CD1d-independent) NKT cell and CD4+
T cell helper responses in response to non-GPI attached PA63 peptides which overall resulted in the
heightened responses seen for this group. Importantly, DNA vaccination mediated the generation of high
avidity neutralizing antibodies that mediated protection against lethal toxin challenge.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Bacillus anthracis, the causative agent of anthrax, has developed
an ingenious strategy to target cells by secreting a soluble proteina-
ceous exotoxin which belongs to a large family of binary (AB type)
pore forming toxins. Formation of anthrax toxins is initiated once
the ‘B’ subunit (protective antigen; PA83) binds to a cell surface
anthrax toxin receptor (ATR), TEM8 and CMG2 [1,2]. PA83 subse-
quently undergoes cleavage by furin resulting in PA63, amembrane
bound protein which forms a heptameric pre-pore of individual
monomers with a !-barrel structure [3,4]. Pre-pore to pore con-
version occurs upon endocytosis triggered by the low pH in the
endosome to form a membrane spanning pore [5,6]. Thus, the ATR
which initially resides in the glycerolipidic, i.e. non-raft regions of
the plasma membrane, upon binding and heptamerization of PA,
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associates with lipid-raft like domains and undergoes rapid endo-
cytosis via clathrin-dependent pathway [7]. All this is undertaken
to ensure the translocation of the catalytically active ‘A’ subunit,
edema factor (EF) and lethal factor (LF), into the cytosolwhere it can
hijack the cellularmachinery [8]. Binding of EF or LF to PA63, which
forms edema toxin (EdTx) and lethal toxin (LeTx), respectively,
occurs at the cell surface after the heptamerization has occurred
[9]. Once in the cytosol, EF, an adenylate cyclase, induces substantial
increase in conversion of intracellular ATP to cAMP in the presence
of calmodulin [10]. Subsequently, water homeostasis and cellular
signaling of host are disrupted resulting in edema [10,11]. LF is
a zinc-dependent metalloprotease that cleaves short N-terminal
fragments from mitogen or extracellular signal-regulated protein
kinase kinase1 (MEK1), MEK2 and MEK3, the upstream activators
of ERK1, ERK2 and p38, respectively [12–14] that disrupts antigen
receptor signaling resulting in macrophage function inhibition and
cell death [14,15].
The depredation thus, resulting from anthrax toxin action
in affected individuals has riveted attention. Early treatment of
anthrax is essential, as antibiotics may not be effective late in
the disease owing to the accumulation of high levels of LeTx and
EdTx even with the elimination of the organism. The licensed
0264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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vaccine, anthraxvaccine absorbed (AVA), suffers fromthe criticisms
of incomplete characterization of the composition of the vaccine,
occasional reactogenicity, and the need for frequent administration
of boosters [16]. Therefore, the current scenario necessitates the
search for newer anthrax vaccines. In this context the potential of
a novel approach that uses DNA for vaccination has been exploited.
Mostof theDNAvaccinationstrategies, testedso far against anthrax,
have relied mainly on DNA-adjuvant combinations for generating
protective immunity [17–25].
The observation that ATR couples raft translocation and medi-
ates endocytosis of EF/LF alongwith theoligomerizationof PAmade
ushypothesize that aDNAchimera encodingprotease-cleaved frag-
ment of PA (PA63) attached to a C-terminal glycosylphosphatidyl
inositol (GPI) anchor sequence might ensure lateral association of
the cell-surface GPI-anchored PA with liquid-ordered, cholesterol-
and sphingolipid-rich domains or rafts. Biochemical, morpho-
logical and functional approaches have been able to trace that
GPI-anchored protein rich rafts are transported down to the endo-
cytic pathway to reducing late endosomes inmammalian cells [26].
Therefore, adoption of such an approach opens up a possibility that
GPI anchored PA63 will undergo its natural cycle upon endocytosis
which might improve DNA vaccine potency.
Based on this rationale we constructed a DNA chimera encoding
GPI-anchored form of PA63 utilizing the mammalian PLAP (Pla-
cental Alkaline Phosphatase) GPI anchor sequence. The GPI signal
appears to have been conserved, however, a mammalian GPI signal
was utilized with the understanding that GPI signals from para-
sitic protozoa are not recognized by mammalian cells [27]. We also
designed a chimera in which PA was attached to an N-terminal TPA
leader along with a C-terminal GPI anchor. TPA is expressed by vas-
cular smooth muscle and binds to a specific cellular receptor p63,
which occurs in fibroblasts as an intracellular protein associated
with the ER [28,29]. The TPA leader peptide can therefore, target
the expressed antigen directly to the ER thus, obviating the need
for the antigen to be processed and translocated to this structure
[30]. Furthermore, ER is also known to be the site where new MHC
and CD1 molecules are synthesized. Both human and murine CD1d
molecules (Group 2 CD1 molecules) have been shown to bind to
GPI-anchored proteins and present them to a variety of CD4+NK1.1+
helper T cells that have been shown to control humoral immunity
against parasites [31] and elicit cell-mediated immune responses
against tumors [32].
Therefore, with these observations in mind we designed the
present study and we successfully illustrated the generation of not
only classical MHC II-restricted immunoglobulin (Ig) responses but
also non-classical CD1d-restricted Ig responses. These responses
generated byGPI-anchored PA63were found to be superior as com-
pared to those generated by native form of PA63 and attributed
to the generation of high frequency of PA-specific NKT cells aris-
ing as a result of DNA vaccination. Also, NKT cells were restricted
to B cells producing antibodies against the GPI-anchored protec-
tive antigen that was captured, internalized and presented in the
CD1d context. Importantly, DNA vaccination mediated the genera-
tion of high avidity toxin neutralizing antibodies which efficiently
protected immunized animals against anthrax LeTx challenge.
2. Materials and methods
2.1. DNA vaccine plasmids and recombinant proteins
DNA manipulations were performed according to standard
molecular biology procedures [33] using the E. coli DH5" strain.
The structural gene for PA63 was cloned in eukaryotic expression
vectors bearing the targeting signals to generate the DNA vaccine
plasmids (for primer sequences refer Table 1, Supplementary infor-
mation, SI). Recombinant PA83 (rPA83) and rPA63 proteins were
obtained from chimeras pMWpag and pSMpag, respectively, cloned
in our lab previously [34]. Peptides (mapped epitopes of PA) used
for in vitro stimulation for cells were synthesized commercially
(Clover ScientificPvt. Ltd., India) at >95%purity. In additionpeptides
representing the mapped epitopes of PA attached to a mammalian
GPI-anchor sequence were also synthesized commercially at >95%
purity. (For Peptide sequences refer Table 2, SI).
2.2. Transfection and immunoblotting
J774A.1 murine macrophage cells were seeded at a concentra-
tion of 2–3×107 cells into a 75-cm2 flask (Corning costar) until
the cells reached approximately 50–70% confluence. Plasmid DNA
transfection was performed with LipofectAMINE 2000 (Invitrogen)
reagent, as specified by the manufacturer. For Western blot anal-
ysis, the transfected cells were washed twice with PBS (pH 7.4)
and lysed in lysis buffer (20mM Tris–HCl (pH 7.6), 150mM NaCl,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dode-
cyl sulfate) 48h post-transfection to prepare total cell lysate. Cell
membraneprotein fractionwas preparedbyQproteomemembrane
protein kit (Qiagen) according to the manufacturer’s protocol. The
presence of cell membrane in the fractions was determined by
the associated NADH oxidase activity [35]. Culture supernatant
proteins were precipitated by ice-cold acetone. Proteins from the
total cell-lysate, cell membrane fractions and culture supernatants
were subjected to SDS–polyacrylamide gel electrophoresis under
denaturing conditions with 50mM dithiothreitol (DTT). Proteins
from the gel were transferred on to a nitrocellulose membrane and
probed with rabbit anti-PA polyclonal serum followed by alkaline
phosphatase-conjugated donkey anti-rabbit IgG (Amersham bio-
sciences). Blot was developed using BCIP/NBT (Sigma–Aldrich) as
substrate.
2.3. Vaccination and lethal toxin challenge
Six- to eight-week-old female Swiss albino outbred mice
(National Institute of Nutrition, Hyderabad, India) were immu-
nized intramuscularly (i.m.) with 100#g of DNA (endotoxin-free)
on days 0, 28 and 56. Mice immunized with rPA83 received recom-
binant protective antigen protein formulated with alhydroxy gel
on days 0 and 28. Pre-immune sera were collected before immu-
nization and thereafter, sera were collected 2 weeks after each
immunization. At different time intervals post the last vaccina-
tion (at week 12, 14, 16, 18, 20), immunized mice were challenged
with anthrax LeTx (50#g of PA83 and 22#g of LF; approximately
4–5 LD50) injected intravenously via tail vein, and the challenged
mice were closely monitored for 21 days. All experiments were
performed in accordance with ‘Indian Animal Ethics Committee’
regulations.
2.4. ELISA detection of anti-PA reactivity in mouse serum
The anti-PA reactivity of sera from immunized animals was
determined by direct ELISA. Briefly, ELISA plates were coated with
rPA63 (10#g/ml) diluted in PBS. Following blocking and washes in
PBS-Tween 20 (0.2%), serum dilutions were added and incubated
for 2h at room temperature. Further, uponwasheswith PBS-Tween
20 (0.2%), plates were incubated either with goat anti-mouse IgG
or IgM HRP conjugate (Santacruz Biotechnology) for 1h at room
temperature. Thereafter, plates were washed with PBS-Tween 20
(0.2%), anddevelopedwith TMBsubstrate (Amershambiosciences).
The reactionwas stoppedwith 1N sulfuric acid, and the plateswere
analyzed at 450nm in an ELISA reader (Benchmark Plus Microplate
spectrophotometer, BioRAD). The negative controls included sera
from mice immunized with PBS and vector. Endpoint antibody
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titers were expressed as the reciprocal of sample dilution at which
the absorption at 450nm was greater than two times the back-
ground signal.
2.5. Detection of toxin neutralizing antibody (TNA) titers
The protective effect of anti-toxin antibodies was determined
using a previously described assay that measures their capacity
to protect the J774A.1 cells from LeTx [36]. Briefly, J774A.1 cells
(5×104 cells/well)were seeded in 96-well, flat bottomplates. After
the cells reached 50–70% confluency, serum dilutions were added
together with LeTx (1.0#g/ml each of PA and LF) and incubated
for 4h. After an additional incubation of 30min after the addi-
tion of MTT (0.5mg/ml) (Sigma–Aldrich), the cells were lysed with
acidic isopropanol (0.04–0.1N HCl in 90% isopropanol). The A450
of 100% viable cells was calculated from the average of four wells
receiving no LeTx. The average of duplicate samples was used to
calculate titers, defined as the reciprocal of the highest dilution of
serum that gives an A450 ≥90% of the value of wells receiving no
LeTx.
2.6. In vitro cell proliferation assay
After isolation, 4×107 spleen lymphocytes from naive or DNA
vaccinated mice were cultured in the presence of pooled peptides
[either GPI-attached PA peptides or non-GPI PA peptides (10#g/ml
of each peptide)] with IL-2 (10U/ml) for a period of 4 days. After
that NK1.1+TCR-"/!+ cells and CD4+ T cells were analyzed by flow
cytometry using fluorescence-activated cell sorting (FACS Van-
tageTSE Flow Cytometry System, Becton Dickinson India Pvt. Ltd.,
Gurgaon 122001, Haryana, India). Monoclonal antibodies against
NK1.1, CD4, and TCR-"/!) were purchased from BD PharMingen
India Pvt. Ltd. The details of the staining and sorting have been
described previously [37]. Clonal expansion in the presence of GPI-
anchor peptide only (Table 2, SI) was subtracted to negate any
proliferation response generated specifically against the glyceroli-
pidic region.
2.7. Isolation of lymphoid cell subsets by FACS
Spleen cells were incubated on nylon wool column for 45min,
and the nonadherent cells were used for the isolation of NKT cells
and CD4+ T cells by cell sorting by FACS. NK1.1, CD4+, and TCR-"/!
cells were identified using monoclonal antibodies (BD PharMin-
gen India Pvt. Ltd.). Unless otherwise noted, CD4+NK1.1+TCR-"/!+
cells were used as purified NKT cells. The stained cells were iso-
lated using the FACS VantageTM. The purity of the sorted cells was
>98%.
2.8. In vitro IL-4 production
NKT cells and CD4+ T cells (105 cells/ml) were incubated with
pooled peptides [either GPI-attached peptides or non-GPI peptides
(10#g/ml of each peptide)] in the presence of splenocyte APCs
(syngeneic splenocytes that were pulsed with peptides and then
given mitomycin-C treatment). Antigen induced IL-4 production
was determined in the presence and absence of anti-MHC II, anti-
MHC I and anti-CD1 monoclonal antibody (BD PharMingen India
Pvt. Ltd.). Cell-free culture supernatants were harvested 24h post-
stimulation and cytokine-specific sandwich ELISA was performed
using OptEIA kit for the specific cytokine (BD PharMingen India Pvt.
Ltd.) according to manufacturer’s protocols. IL-4 production in the
presence of GPI-anchor peptide only (Table 2, SI) was subtracted
to negate non-specific stimulation due to the glycerolipidic region
only.
2.9. B-lymphocyte purification
After isolation, splenocytes were incubated with anti-CD43 and
anti-Mac-1 antibody-conjugatedmicrobeads (Miltenyi Biotec India
Pvt. Ltd.). The bead-bound cells (positive fraction) were separated
from unbound cells (negative fraction) using an AutoMacs mag-
netic cell sorter. The enriched cell population was subjected to
multiparameter cell sorting by FACS to separate cells express-
ing B220, a marker present on cells committed to the B lineage
[38]. The preparation was 96% B220+, the few contaminants were
CD43+/Mac-1+.
2.10. Helper assays
B lymphocytes (2.5×105/ml) were co-cultured in the pres-
ence of NKT cells, CD4+ helper T cells or alone in the presence
of either, GPI or non-GPI-PA peptides (pooled peptides, 10#g/ml)
and IL-2 (10U/ml). Antigen specific IgG production was quan-
tified upon addition of anti-class II and anti-CD1 mAb by
ELISPOT. IgG production in the presence of GPI-anchor pep-
tide only (Table 2, SI) was subtracted to negate non-specific
stimulation due to the glycerolipidic region only. Spots were
developed using Alkaline Phosphatase-linked secondary anti-
body and BCIP/NBT (Sigma–Aldrich) as substrate. Results were
expressed as number of SFU (Spot Forming Units) per 106
cells.
2.11. Determination of avidity of PA-specific IgG antibodies
Antibody avidity was measured by using a previously described
ELISA that utilizes urea as chaotropic agent to dissociate low-
affinity antigen–antibody complexes [39].
2.12. Statistical analysis
The experimental data were analyzed by software programs
Sigma Plot 8.1 or Excel (Microsoft). The statistical significance
of differences was analyzed by a two-tailed Student’s t-test for
independent groups (followed by Bonferroni’s correction to adjust
for multiple comparisons). A p value of <0.05 determined was
considered statistically significant. Correlation coefficients were
determined by linear regression analysis.
Fig. 1. The address tags efficiently target PA63 to various sub-cellular locations.
Shows expression of different forms of protease-cleaved fragment of protective
antigen in J774.A1 mouse M!-like cells. Cells were transfected with DNA vaccine
constructs. Cell lysates and cell membrane fractions were prepared 48h post-
transfection. Along with that cell culture supernatant proteins were harvested by
acetoneprecipitation. Subsequently, the protein sampleswere subjected to 12%SDS-
PAGE under reducing conditions and transferred onto a nitrocellulose membrane.
Blot was probed with anti-PA polyclonal serum followed by alkaline phosphatase-
conjugated donkey anti-rabbit IgG and developed using BCIP/NBT as substrate.
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Table 1
Anti-PA antibody titers in the serum of DNA immunized animals.
Construct Antibody endpoint titersa, 103 ± SD
IgM IgG TNA
Priming 1st Boost 2nd Boost Priming 1st Boost 2nd Boost Priming 1st Boost 2nd Boost
pGPI-PA63 0.48±0.1 <0.05 <0.05 25.0±4.0 47.0±6.5b,c 79.0±4.1b,c −BD 0.35±0.11b 0.51±0.2b
pTPA.GPI-PA63 0.55±0.2 <0.05 <0.05 13.5±1.5 88.0±5.5b,c 100±4.0b,c −BD 0.75±0.23b 1.0±0.15b
pPA63-Native 0.37±0.2 <0.05 <0.05 3.5±0.5 10.0±2.0 20±2.1 −BD 0.10±0.01 0.15±0.1
rPA83 0.40±0.4 <0.05 <0.05 18.5±0.5 58.0±5.0b,c 70.0±2.1b,c −BD 0.27±0.05 0.39±0.1b
Vector control −BDd −BD −BD −BD −BD −BD −BD −BD −BD
a Mice were immunized on days 0, 28 and 56; and anti-PA titers were measured in the serum of the immunized mice 14 days after each immunization. Results represent
titers obtained for 8–10 mice tested in a group in three independent experiments and results are expressed as mean ±SE.
b Significantly higher (p<0.001) titers as compared to the pPA63-Native group as calculated by Student’s t-test followed by Bonferroni’s correction to adjust for multiple
comparisons.
c Significantly higher (p<0.01) titers as compared to those developed after priming.
d Below detection.
3. Results
3.1. Transfection of DNA vaccine chimeras in J774A.1!-like cells
followed by detection with Western blotting
The structural gene for PA63 was cloned in DNA vaccine plas-
mids bearing the address tags (GPI, TPA-GPI). Authenticity of
the DNA constructs was evaluated by transient transfection in
J774A.1 cells with DNA chimeras followed by subcellular frac-
tionation and immunoblot analysis (Fig. 1). Results indicated
that the PA63 protein along with the GPI and TPA signals was
being properly recognized by the mammalian cells. The DNA
chimeras, pGPI-PA63 and pTPA.GPI-PA63, expressed membrane-
anchored form of PA63 (Fig. 1). In addition, the chimera
pTPA.GPI-PA63 also mediated secretion of PA63 in the culture
supernatants.
3.2. Significant high avidity antibody responses were generated in
the vaccinated mice
Following i.m. injection of the DNA constructs, 100% of the mice
had strong serum IgM titers (Table 1) which peaked after prim-
ing and then declined after administering the first and second
booster dose. Pronounced PA-specific IgG titerswere demonstrated
by groups that were immunized with chimeras encoding the
GPI-anchored form of PA63. Highest titers were elicited by the
chimera pTPA.GPI-PA63 (≈100,000), followed closely by the groups
pGPI-PA63 (≈79,000) and rPA83 (≈70,000) which also generated
Table 2
Antibody response and protection against B. anthracis LeTx challenge at different time points post-vaccination.
Group Time of challengea (week) Antibody titers post-challenge, 103 ± SD
Total anti-PA antibody LeTx neutralizing antibody Survival% (No. of survivors/No. challenged) MTDb ± SE (days)
pGPI-PA63 12 85.5±5.5 0.88±0.20 100 (9/9)
14 91.4±8.8c 0.90±0.10c 100 (8/8)
16 90.5±7.0c 0.94+0.20c 100 (7/7)
18 80.1±6.5 0.70±0.15 75 (6/8) 9.5 ± 0.50c
20 80.5±7.5 0.69±0.12 75 (5/7) 8.9 ± 0.40
pTPA.GPI-PA63 12 120±5.5 1.30±0.50 100 (8/8)
14 199±6.0c 1.95±0.40d 100 (8/8)
16 175±8.0c 1.70±0.20d 100 (5/5)
18 155±3.0 1.55±0.15 100 (7/7)
20 140±2.0 1.51±0.11 100 (8/8)
pPA63-Native 12 26.0±4.0 0.19±0.05 43 (3/7) 3.6 ± 0.61
14 41.0±6.5 0.25±0.02 56 (5/9) 5.9 ± 0.25
16 34.0±3.5 0.24±0.03 56 (5/9) 5.7 ± 0.52
18 20.0±2.5 0.19±0.03 44 (4/9) 3.6 ± 0.55
20 19.0±2.5 0.18±0.05 44 (4/9) 3.3 ± 0.60
rPA83 12 53.5±9.0 0.58±0.10 63 (5/8) 5.6 ± 0.60
14 88.0±15.5c 0.72±0.15d 78 (7/8) 9.5 ± 0.20c
16 87.9±12.5c 0.68±0.12d 78 (7/8) 9.7 ± 0.15c
18 78.0±15.5 0.60±0.21 70 (7/9) 8.9 ± 0.30
20 79.5±14.5 0.59±0.20 69 (7/9) 8.8 ± 0.20
Vector control 12 −BDe −BD 0 (0/5) 0.70 ± 0.12
14 −BD −BD 0 (0/4) 0.65 ± 0.15
16 −BD −BD 0 (0/4) 0.75 ± 0.20
18 −BD −BD 0 (0/5) 0.70 ± 0.16
20 −BD −BD 0 (0/6) 0.70 ± 0.20
a The immunized mice were challenged at 12, 14, 16, 18, 20 weeks post-immunization with LeTx injected i.v. through tail vein and monitored for 21 days. Results represent
titers obtained for n=9 mice tested in a group in three independent experiments and results are expressed as mean ±SE.
b MTD, mean time to death was determined by determining the average time to death for each group, excluding the survivors. Results are represented as MTD± SE.
c Significantly higher (p<0.01) titers as compared to the pPA63-Native group as calculated by Student’s t-test followed by Bonferroni’s correction to adjust for multiple
comparisons.
d Significantly higher (p<0.001) titers as compared to the pPA63-Native group.
e BD, below detection.
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Table 3
Avidity indices of anti-PA antibodies in the serum of immunized mice.
Construct Antibody avidity indexa
Day 70 Day 100 challenge Day 28 post-challenge
pGPI-PA63 33 62b,c 78b,c
pTPA.GPI-PA63 39 79b,c 87b,c
pPA63-Native 23 34 53c
rPA83 30 75b,c 88b,c
Vector control −BDd −BD −BD
a Avidity index= (endpoint titer in the presence of urea)/(endpoint titer in the
absence of urea))×100.
b Significantly higher (p<0.001) avidity index as compared to the pPA63-Native
group as calculated by Student’s t-test followed by Bonferroni’s correction to adjust
for multiple comparisons.
c Significantly higher (p<0.01) as compared to the AI at day 70.
d No PA-specific antibody was detected.
significant titers (p<0.001 vs. pPA63-Native group) after the sec-
ond boost. Importantly, these titers were maintained until week
20 post-priming (Table 2). Evaluation of TNA titers revealed that
Letx neutralization activity was measurable only after the first
booster dose (Table 1). TNA titers were approximately 2–3 times
higher in the serumof animals immunizedwithpTPA.GPI-PA63 and
pGPI-PA63 than the animals vaccinated with the native construct
lacking the GPI anchor. Sera from control mice did not neutralize
anthrax LeTx at all. The group immunized with rPA83 formulated
with alhydroxy gel also generated significant TNA titers measur-
ing≈390 which was twice as compared to the pPA63-Native group
but only after the second booster dose was administered (p<0.001
vs. pPA63-Native group, Table 1). Evaluation of the antibody avidi-
ties revealed that high avidity antibodies were generated only at
the time of challenge on day 100 (Table 3). Groups immunized
with pTPA.GPI-PA63, pGPI-PA63 and rPA83 showed highest avid-
ity indices (AI) of 79, 62 and 75, respectively, whereas the group
pPA63-Native showed a significantly lower AI value of 34. Four
weeks post-challenge, a further increase in AI was observed for all
the groups (Table 3) with groups pTPA.GPI-PA63, pGPI-PA63 and
rPA83, showing avidities as high as 87, 78 and 88, respectively, as
opposed to an AI =53 for the pPA63-Native group.
3.3. CD4+ NK1.1+ helper-T cells were generated upon vaccination
with GPI anchored form of PA63
Flow cytometric analysis revealed that there was a marked
increase in both the absolute and relative numbers of CD4+ NK1.1+
helper T cell (NKT) population after 5-day culturing in the pres-
ence of GPI-attached PA63 peptides (Fig. 2). The relative numbers
of NKT cells after in vitro proliferation was astonishingly higher
for the groups immunized with chimera pGPI-PA63 (75.7%) and
pTPA.GPI-PA63 (71.5%), as compared to those immunized with
pPA63-Native (5%) and rPA83 (1.5%). Importantly, this prolifera-
tion response also resulted in 18.7%CD3+CD4+ (CD4+"/!TCR+) cells
from the pTPA.GPI-PA63 group which otherwise displayed a higher
number of CD3+CD4+ (45.3%) when the splenocytes were cultured
in the presence of non-GPI-PA63 peptides. The NKT cell population
from this group also proliferated rapidly in the presence of non-GPI
PA63 peptides but the relative number of NKT cells proliferating in
response to GPI-attached PA63 peptides (71.5%) was quite higher
as compared to those proliferating in response to non-GPI PA63
peptides (39.7%). The groups immunized with the chimera pPA63-
Native and rPA83, on the other hand, solely gave rise to CD4+ T cell
population (55.7% and 85.5%, respectively) in the presence of non-
GPI PA63 peptides only. Overall, chimera pTPA.GPI-PA63 resulted in
proliferation of both CD4+ T and CD4+ NKT-cell populationwhereas
pGPI-PA63 chimera resulted in clonal expansion of NKT-cell popu-
lation inmajority, in response to GPI-attached PA63 peptides. Thus,
the NKT cell population from the group pTPA.GPI-PA63 responded
well against both GPI-attached and free PA63 peptides whereas
pGPI-PA63 responded only against the GPI-attached PA63 peptides.
3.4. Combined CD1d- and MHC II-restricted IL-4 responses were
generated by chimera pTPA.GPI-PA63
Fig. 3 shows IL-4 production by NKT cells isolated from immu-
nizedmicewhen co-culturedwith splenocyte APCs in the presence
of GPI-attached and free PA63 peptides. NKT cell-mediated IL-4
production in the presence of GPI-attached PA63 peptides was
completely abrogated by anti-CD1 mAb in both the groups that
received pTPA.GPI-PA63 and pGPI-PA63 chimeras (Panels A and E).
These responses on the other hand were completely unaffected by
anti-MHC II mAb pointing that GPI-anchored PA63 was efficiently
processed and presented in contextwith CD1molecule to NKT cells
in these groups. The group immunized with pPA63-Native did not
show any NKT cell mediated IL-4 production in the presence of
GPI-attached or non-GPI PA63peptides (Panels I andK). On the con-
trary, NKT cells isolated from the group pTPA.GPI-PA63 displayed
NKT cell mediated IL-4 production in the presence of non-GPI
PA63 peptides (Panel F). Interestingly, these responses were totally
abrogated by anti-MHC II mAb but were completely unaffected by
anti-CD1 mAb. Also, evaluation of CD4+ "/! TCR+ T cell-mediated
IL-4 responses indicated that the CD4+ T cells isolated from the
group pTPA.GPI-PA63 and pPA63-Native produced IL-4 only when
they were presented with non-GPI PA63 peptides (Panels H and L).
This lysis was completely abrogated by anti-MHC II mAb and was
totally unaffected by anti-CD1 mAb indicating that the antigen was
presented in contextwithMHC-IImolecules. On theother hand IL-4
production by CD4+ helper T cells isolated from the group pGPI-
PA63 was insignificant in the presence of both the forms of PA63
peptides (Panels C and D). Furthermore, the IL-4 secretion pattern
of the group that received rPA83 formulatedwith alhydroxy gelwas
found to be similar to that obtained for the pPA63-Native group and
the responses were not significantly different. Overall, the results
provided evidence that NKT cells from the group pTPA.GPI-PA63
mediated CD1d- and MHC-II restricted IL-4 responses against GPI-
as well as non-GPI forms of PA63, respectively. CD4+ T cells gener-
ated IL-4 responses exclusively against the non-GPI form of PA63.
Also, MHC I-restricted responses had no role to play.
3.5. CD1d- and MHC II-restricted help to B cells aided IgG
formation
We co-cultured autologous B lymphocytes with NKT cells in the
presence ofGPI-attachedPA63peptides to assessNKT cell aided IgG
formation (Fig. 4). As expected, NKT cells isolated from the group
pTPA.GPI-PA63andpGPI-PA63extendedefficienthelp toB lympho-
cytes for IgG formation (Panels A and E, Fig. 3). This response was
also dependent upon CD1d-restriction of the GPI-attached PA63
peptides as high SFCs (Spot Forming Cells) were obtained only
in the absence of anti-CD1d antibody. However, such a response
was slightly higher for the group pGPI-PA63 which developed SFU
≥600 as compared to the group pTPA.GPI-PA63 which also dis-
played a high SFU of ≈600 (Panels A and E). Importantly, the group
pTPA.GPI-PA63 also displayed MHC II-restricted NKT cell mediated
IgG responses against non-GPI PA63 peptides (Panel F) as opposed
to only CD1d-restricted responses seen for the group pGPI-PA63
(Panels A and B). In addition to this, CD4+ T cell-mediated B cell
helper responses to non-GPI PA63 peptides were also evaluated.
These results were in corroboration with those obtained for IL-4
productionandalsodetailed thegenerationofMHC II-restricted IgG
responses to non-GPI PA63 peptides, by the groups pTPA.GPI-PA63,
pPA63-Native and rPA83 (Panels H, L and P; respectively).
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Fig. 2. CD4+ NK1.1+ helper-T cells were generated upon vaccination with GPI anchored form of PA63. Mice were immunized i.m. with different DNA vaccine constructs. At day
70 mice were euthanized to take out the spleens and spleen cells were cultured in the presence of pooled peptides [either GPI-attached PA peptides or non-GPI PA peptides
(10#g/ml of each peptide)] with IL-2 (10U/ml) for a period of 4 days. Thereafter, NK1.1+TCR-"/!+ cells and CD4+ T cells were analyzed by flow cytometry.
3.6. Correlation between TNA/anti-PA titers and protection of
mice against Letx toxin challenge
Immunized mice were challenged with a LeTx mixture (50#g
PA and 22#g LF,≈4–5 LD50) in a total volume of 100#l via tail vein
injectionatdifferent time intervals (week12, 14, 16, 18and20)post-
immunization. Toxin challenge results as obtained are summarized
in Table 2. Control mice (vector immunized) died after receiving an
anthrax LeTx injection with a MTD (Mean Time to Death) around
0.7±0.2days. All themice immunizedwithpTPA.GPI-PA63 resisted
toxin challenge and elicited a survival percentage of 100% at all the
time intervals post-immunization (Table 2). The average TNA and
anti-PA titers for this group corresponded to≥103 and≥105, respec-
tively. On the other hand, the group pGPI-PA63 showed a 100%
survival till week 16 with average TNA titers for protection ranging
between 880 and 940. TNA titers below this range (680–700) con-
ferred protection to 75% of the mice and increased MTD to 8.9–9.5
days. Results also depicted that both anti-PA and TNA titers lev-
eled off at titers about ≥105 and ≥103 respectively, for the group
pTPA.GPI-PA63; and ≥80,000 and 700, respectively, for the group
pGPI-PA63 post-week 14. For the group pPA63-Native, TNA titers
ranging from 180 to 250 conferred protection to 43–56% of the
mice with an average MTD ranging from 3.3 to 5.9 days. On the
other hand, TNA and anti-PA titers of ≈700 and ≈70,000 provided
protection to 78% of the animals immunized with rPA83, with an
average MTD of 9.0–9.5 days.
Statistical differences between the delays in time-to-death as
measured by log rank statistic for the groups immunized with GPI-
bearing chimeras compared to the vector control group showed
that the differences were quite significant (p<0.01) and correlated
well with survival (r=0.85). Analysis of post-challenge TNA titers
showed that survival at week 14 and 16 correlated well with each
other (r=0.89). The results therefore, suggested that mice immu-
nized with DNA vaccine chimeras bearing GPI-anchor sequence
developed significant TNA titers which protected the mice against
anthrax lethal toxin challenge. Importantly, DNA immunization
alone with the chimera pTPA.GPI-PA63 provided 100% protection
to animals till week 20 post-priming.
4. Discussion
Although the currently licensed anthrax vaccine generates
potential anti-anthrax immunity, it suffers from drawbacks like
occasional reactogenicity, an extended dosage schedule, and fre-
quent administration of boosters. Clearly, there is reason to explore
alternatives. Therefore, based on the hypothesis that GPI-anchored
form of PA will improve DNA vaccination against anthrax, we con-
structed a DNA chimera encoding the protease-cleaved fragment
of protective antigen (PA63) attached to a C-terminal mammalian
PLAP (Placental Alkaline Phosphatase) GPI anchor sequence. Along
with that we constructed another chimera bearing PA63 gene with
an N-terminal TPA leader alongwith a C-terminal PLAP-GPI anchor.
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Fig. 3. Combined CD1d- and MHC II-restricted IL-4 responses were generated pTPA.GPI-PA63 chimera. Mice were immunized i.m. with different DNA vaccine constructs. At
day 70 mice were euthanized to take out the spleens and spleen cells were used for the isolation of CD4+ NK1.1+ helper T cells and CD4+ T cells by cell sorting using FACS
VantageTM instrument. NKT cells and CD4+ helper T cells were cultured in the presence 10#g/ml GPI-PA63 and non-GPI-PA63 peptides to determine the cytokine secretion
in vitro. Cell-free supernatants were collected 24h. Each bar represents the concentration of IL-4 secreted by NKT cells/CD4+ T cells from 9 mice in a group tested in three
different experiments and error bars represent the ±SEM. (The error bars represent 95% confidence intervals calculated from the group wise mean concentration. *, **, ***,
and ****, represent significant difference of the response relative to pPA63-Native immunization defined as p<0.0001, p<0.001, p<0.01and p<0.05, respectively).
In vitro expression of the chimeras in the J774A.1 cells was
evaluated to test whether the gene for PA63 and the signals were
beingproperly recognized in themammalian cells. Subcellular frac-
tionation and Western blotting indicated that the PA63 protein
along with the GPI and TPA signal was being properly recognized
by the mammalian cells. The chimeras, pGPI-PA63 and pTPA.GPI-
PA63, expressedmembrane-anchored formof PA63. In addition, the
chimera pTPA.GPI-PA63 also mediated the secretion of PA63 in the
cell culture supernatants.
Earlier studies have underscored the importance of anti-PA anti-
bodies in anti-spore activity and suggested their role in impeding
the early stages of infection with B. anthracis spores [40]. Also,
passive transfer of anti-PA antibodies has been shown to provide
protection against anthrax infection in guinea pigs [41]. Therefore,
to test the ability of GPI anchored PA63-expressing chimeras to
generate protective humoral responses in vivo, we injected mice
with the DNA chimeras and determined the anti-PA reactivity in
the serum of the immunized animals. Evaluation of IgM titers post-
inoculation suggested successful priming. Remarkable serum IgG
antibody titers were observed after the second booster for both
the groups immunized with the constructs encoding GPI-anchored
form of PA. These responseswere approximately two to three times
higher than those generated by pPA63-Native chimera indicat-
ing that GPI-anchored forms evoked better PA-specific humoral
responses than the non-GPI anchored form of PA. Importantly,
electron microscopic studies have shown that spore-associated
proteins can be recognized by anti-PA antibodies, and PA-immune
serum from several species enhanced the phagocytosis of spores
of the virulent Ames and Sterne strains by murine peritoneal
macrophages [40,42,44]. In addition, it has been shown that IgG
antibodydisplays highest affinity towards PA [43]. Therefore, devel-
opment of high endpoint titers of anti-PA IgG antibody upon DNA
vaccination gains high merit from anti-spore activity point of view.
TNA titerswere also analyzed andwere again found to be higher
for the groups that received chimeras encoding GPI-anchored form
of PA. TNA titers after attaining a peak at week 14, first declined
and then plateaued. This decline in neutralization titer paralleled
the declining survival percentage supporting the notion that anti-
bodies involved in neutralization are the ones that afford protection
against LeTx challenge. This was also shown by the increased delay
indeath inpartiallyprotectedmiceas compared to the controlmice.
Statistical differences between the delays in time-to-death as
measured by log rank statistic for the groups immunized with GPI-
bearingchimeras compared to thevector control groupshowedthat
the differences were quite significant (p<0.01) and correlated well
with survival (r=0.85). Further, survival at week 14 and 16 corre-
lated well with the TNA titers developed at these two time points
(r=0.89). Anti-PA titers of≥105 and TNA titers≥103 mediated resis-
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Fig. 4. CD1d- and MHC II-restricted help to B cells aided IgG formation. Mice were immunized i.m. with different DNA vaccine constructs. At day 70 mice were euthanized
to take out the spleens and spleen cells were used for the isolation of CD4+ NK1.1+ helper T cells and CD4+ T cells by cell sorting using FACS VantageTM instrument. NKT cells
and CD4+ helper T cells were cultured in the presence 10#g/ml GPI-PA63 and non-GPI-PA63 peptides to determine IgG formation in vitro as determined by ELISPOT assay.
ELISPOT data is expressed as mean Spot Forming Cells (SFC’s)± SE of the Ag-stimulated cells minus un-stimulated cells. Each bar represents number of SFC’s obtained for 9
mice in a group tested in three different experiments. (The error bars represent 95% confidence intervals calculated from the groupwisemean SFC. *, **, ***, and ****, represent
significant difference of the response relative to pPA63-Native immunization defined as p<0.0001, p<0.001, p<0.01and p<0.05, respectively.).
tance against toxin challenge and conferred 100% protection to the
animals in the group pTPA.GPI-PA63. Recombinant PA83 immu-
nization, on the other hand, conferred only 78%protection response
with average TNA and anti-PA titers of ≈700 and ≈70,000. Such a
correlation between protection and neutralization titers has also
been observed in other animal models like guinea pigs [45,46]
and rabbits [47] suggesting that this phenomenon is not species-
specific. Additionally, evaluation of antibody avidities depicted a
progressive increase in the avidity of the antibodies on subse-
quent immunizations. Further investigation of memory responses
in terms of affinity maturation of antibodies (antibody avidity)
upon challenge indicated that a challenge engendered anamnes-
tic immune response was mounted. Taken together, these TNA and
anti-PA antibodies generated upon immunization with the GPI-
anchored forms of PA can efficiently confer protection against both
toxemia and bacteremia, thus, providing armour against infection.
To determine the fine specificity of the T cell subsets generated
upon DNA vaccination we examined the in vitro proliferation of
the splenocytes in the presence of GPI-attached- as well as non-
GPI-PA63 peptides. Our results revealed that NKT cells were the
main target for activation by GPI-anchored PA63 peptides. These
results were consistent with the seminal study which illustrated
that cellular GPI and glycolipids are natural ligands of mouse CD1d,
a member of CD1 family of evolutionarily conserved MHC-like
molecules [48]. These CD1d molecules in turn have been shown
to directly control the function of NK1+ natural killer T (NKT) cells,
a heterogenous subset of T cells displaying a CD4+ or CD4−CD8−
double negative phenotype, and co-expressing the natural killer
cell receptor NK1.1/NKR P1A and a semi-invariant TCR encoded in
mice [49]. Interestingly, an appreciable number of NKT cells also
proliferated in the presence of non-GPI PA63 peptides, from the
group pTPA.GPI-PA63 indicating that NKT cells isolated from this
group responded well against both GPI as well non-GPI attached
forms of PA63. However, NKT cells clonally expanded to relatively
higher numbers in the presence of GPI-attached PA peptides as
compared to non-GPI-associated PA peptides. Results therefore,
point that somehow the post-translational modifications of the
expressed antigen in the mammalian systems in vivo affected their
ability to activate innate immunity.
Generation of Ig responses against an antigen is as a result of
classical MHC-II-dependent “cognate-help” which requires BcR-
mediated antigen internalization and presentation of specific
epitopes to antigen-specific T cells [50]. Studies however, suggest
a direct role for invariant CD4+ NKT cells in regulating CD1d-
restricted B cell help which regulates B lymphocyte proliferation
and effector functions [51]. Therefore, to establish the restric-
tion requirements of this NKT cell lineage, we evaluated the IL-4
responses and NKT cell mediated IgG formation. We show here
that the recognition of GPI-anchored PA63 by the NKT cells (from
groups pGPI-PA63 and pTPA.GPI-PA63) is MHC-independent and
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CD1-restricted. However, analysis of similar responses by CD4+
helper T cells isolated from the groups, pTPA.GPI-PA63, pPA63-
Native and rPA83 indicated that these responses were on account
of MHC II-mediated restriction of non-GPI-attached PA63. Inter-
estingly, NKT cells from the group pTPA.GPI-PA63 displayed MHC
II-restrictionandCD1-independencewhenpresentedwith thenon-
GPI PA63 peptides.
Why the groups pTPA.GPI-PA63 and pGPI-PA63 mainly dis-
played CD1d restricted responses: was the next question we
addressed. There are reports that have shown that GPI-anchored
proteins occur as microdomains in cell membrane in living cells
[52]. In this manner the alkyl acyl chain of the GPI-anchored pro-
teins can make contacts with the CD1 pocket on the cell surface
on account of the unique capacity of CD1 molecules to bind and
exchange lipids also on the cell surface [53]. Therefore, the gen-
eration of predominantly CD1d-restricted NKT cell responses by
the group pGPI-PA63 and pTPA.GPI-PA63 could probably be as a
result of the cell surface recognition of membrane-anchored PA63
by CD1d molecules. However, the NKT cells and CD4+ helper T cells
isolated from the group pTPA.GPI-PA63 also displayed Ig responses
to non-GPI anchored PA63 that were MHC-II restricted and CD1-
independent which suggested that the antigen expressed by this
chimerawas being channeled toMHC II pathway aswell. This could
possibly be as a result of deacylation of the expressedGPI-anchored
antigen either in ER or upon secretion by endogenous host phos-
pholipases.
TPA is a protein that is expressed by vascular smooth muscle
and binds to a specific cellular receptor p63, occurs in fibroblasts
as an intracellular protein associated with the ER [28,29]. The TPA
leader peptide possibly mediated targeting of the expressed anti-
gen directly to the ER. As matter of fact, TPA leader peptide has
also been shown to mediate the secretion of the proteins attached
to them [54,55]. This was also seen in our case following in vitro
transfection and immunoblot analysis (Fig. 1). This secreted (pos-
sibly deacylated) protein was taken up as an extracellular protein
by endocytosis and channeled to MHC II pathway as indicated by
abrogation of effector responses generated by NKT cells and CD4+T
helper T cells upon addition anti-MHC II mAb (Figs. 3 and 4). Over-
all, there was successful antigen trafficking to both pathways of
antigen presentation that is CD1 as well as MHC II in response to
GPI-anchored and non-GPI anchored forms of PA, respectively.
To our knowledge there is no publishedwork demonstrating the
development of NKT cell mediated helper responses generated by
combined CD1d- and MHC II-restriction of the antigen delivered
via i.m DNA vaccination. These NKT cells were CD1d reactive and
upon antigen recognition responded en masse, leading in turn to a
variety of effects on the immune system. Generation of such rapid
responses in vivo by NKT cells arising as a result of DNA vaccina-
tion can contribute to the development of intermediate immunity
between pattern recognition and adaptive immune system [31].
Also, NKT cells can restrict B cells in vivo resulting in antibodies
against the GPI-anchored antigen that would be captured, internal-
ized and presented in the CD1d context [51].
Importantly, bothmouse andhumanCD1dmolecules arewidely
broadly distributed on most cells of hematopoietic origin, with the
highest levels observed on leukocytes such as dendritic cells, B cells
ormonocytes that will assure constant immune surveillance. Addi-
tional help provided by the classical MHC II restricted NKT- and
CD4+ T-helper cell responses further resulted in the augmentation
of useful responses. Overall, we successfully illustrate here the gen-
eration of efficient humoral responses against anthrax protective
antigen that generated protective immunity against anthrax lethal
toxin challenge. Further work can gain a complete understanding
regarding the immune pathways involved which can ultimately
lead to the design and development of better human vaccines
against anthrax to counter emergency.
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